RXi Pharmaceuticals, a Worcester, MA-based developer of drugs based on RNA interference technology, said today it has obtained an exclusive worldwide license to certain technology for oral delivery of RNAi drugs. The technology was developed by Michael Czech and Gary Ostroff at the University of Massachusetts Medical School. Financial terms were not disclosed.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
